Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph not_applicable
3
38%
Ph phase_2
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (57.1%)
N/A3 (42.9%)

Trials by Status

terminated113%
completed675%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

NCT03458260
completednot_applicable

Donor After Circulatory Death Heart CAP Trial

NCT04615182
completednot_applicable

TRANSEURO Open Label Transplant Study in Parkinson's Disease

NCT01898390
terminatedphase_2

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

NCT03709576
completed

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

NCT02182986
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03458260Phase 2

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Completed
NCT04615182Not Applicable

Donor After Circulatory Death Heart CAP Trial

Completed
NCT01898390Not Applicable

TRANSEURO Open Label Transplant Study in Parkinson's Disease

Completed
NCT03709576Phase 2

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Terminated
NCT02182986

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Completed
NCT00449319Not Applicable

AML Treatment in Untreated Adult Patients

Unknown
NCT00006747Phase 2

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed
NCT00462332Phase 2

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Completed

All 8 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
8